JC07 Ree'd PCT/PTO PATENT

DOCKET NO. BM45396

٠,٠

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **BOX PCT/DO-EO**

Commissioner for Patents Washington, DC 20231

"Express Mail" mailing label number EL 823 533 203 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: BOX PCT/DO-EO Commissioner for Patents, Washington, DC 20231, on December 13, 2001.

> NATIONAL STAGE APPLICATION TRANSMITTAL LETTER APPLICATION FILING UNDER 35 U.S.C. § 371

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s):

Thonnard, Joelle

**International Application No.:** 

PCT/EP00/05851

International Published Appln. No.: WO 01/00836 **International Filing Date:** 

23 June 2000

**Priority Filing Dates:** 

25 June 1999

**Thirty Month Date:** 

**25 December 2001** 

Title:


"NOVEL COMPOUNDS"

THIS NEW APPLICATION IS A <u>NATIONAL STAGE</u> APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR **EXAMINATION WITHOUT DELAY TO THE UNITED STATES** DESIGNATED/ELECTED OFFICE (DO/EO/US).

$\boxtimes$	This is a FIRST submission of items concerning a filing under 35 U.S.C						
	371;						

This is a SECOND or subsequent submission of items concerning a filing
under 35 U.S.C. § 371.

This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).



3. month		oper Demand for International Preliminary Examination was made by the 19 <sup>111</sup> the earliest claimed priority date.					
4. 1.495(		ed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or §					
	$\boxtimes$	One copy of International Publication No. WO 00/00836					
	(a)	is transmitted herewith (required only if not transmitted by the International Bureau)					
	(b)	has been transmitted by the International Bureau					
	(c)	is not required, as the application was filed in the United States Receiving Office (RO/US)					
<u>Fees</u>							
	$\boxtimes$	The basic national fee set forth in 37 CFR § 1.482 - International Preliminary					
	nation F <b>\$890.00</b>	ee not paid to USPTO but International Search Report prepared by the EPO or					
	$\boxtimes$	Claims in Excess of 20 (3 @ \$18.00)					
		Independent Claims in Excess of 3 (@\$84.00)					
5.	Furthe	r enclosed are:					
	$\boxtimes$	One copy of International Preliminary Examination Report.					
	$\boxtimes$	One copy of International Search Report.					
		One copy of Written Opinion.					
		One copy of PCT Request as filed.					
		One copy of Chapter II Demand as filed.					
6. 371(c)	(2))	A translation of the International Application into English (35 U.S.C. §					
7. 19 (35	U.S.C.	Amendments to the claims of the International Application under PCT Article § 371(c)(3))					
8. § 371(	(c)(3))	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C.					
9.	Still additional papers enclosed:						
		Assignment with Assignment Recordation Form Cover Sheet					
		Verification Statement Claiming Small Entity Status					
		Declaration or oath is enclosed executed by the inventor					
	$\boxtimes$	An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98					
	$\boxtimes$	Return Acknowledgment Postcard					

11.



10.	Nucle	leotide and/or Amino Acid Sequence Submission (if applicable, all necessary)				
A.	Enclosed are:					
	(a)	$\boxtimes$	Computer Readable Copy of the Sequence Listing			
	(b)	$\boxtimes$	Paper Copy (identical to Computer Readable Copy) of the			
			Sequence Listing			
B.		Enclo	sed is a paper copy of the Sequence Listing. This paper copy and			
		a Computer Readable Form thereof are identical with the Computer				
		Readable Form in another application of the Applicant which is fully				
		identi	fied as follows:			
			U.S. Application No.: @@			
			Filed: @@			
			Attorney Docket No.: @@			
		which	is believed to comply with the rules set forth in 37 CFR § 1.821			
		et. se	q. Applicants requests pursuant to 37 CFR § 1.821(e) that this			
		Comp	outer Readable Form be used in the present application. Please			
		TRANSFER the sequence listing from the parent to this				
		appli	cation.			
C.	$\boxtimes$	States	ment under 37 CFR § 1.821(f): The information recorded in			
		comp	uter readable form is identical to the written Sequence			
		Listir	ng.			
D.		State	ment under 37 CFR § 1.821(g) (required when Sequence Listing			
		not su	abmitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR			
		§1.82	1(f) (required when Sequence Listing not submitted at the time of			
		filing	under the Patent Cooperation Treaty): The submission of the			
		Sequ	ence Listing includes no new matter.			
E.		Amer	ndment: Please enter the Sequence Listing into the application.			
<u>Prelii</u>	minary	Ameno	<u>lment</u>			
Prior	to calcu	lation o	of fees, kindly enter:			
$\boxtimes$	Preliminary Amendment submitted herewith					
	do not enter Preliminary Amendment					

10/018561

Rec'd PCT/PTQ<sub>ATEN</sub> DEC 2001

DOCKET NO. BM45396

12. The correspondence address for this application is the Customer No. provided below:

## **Insert Bar Code Label Here:**



25308

13. Fee payment being made at this time is enclosed:

*	Basic filing fee (\$890.00)	890.00
*	Claims in Excess of 20	54.00
*	(3 @ \$18.00)	
	Independent Claims in Excess of 3	00.00
	( @ \$84.00)	

\* Total Fees enclosed: \$944.00

14. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,

Teresa O. Bittenbender Registration No. 47,425 Attorney for Applicant

DECHERT 1717 Arch Street 4000 Bell Atlantic Tower Philadelphia, PA 19103 Fax: (215) 994-2222

Attn.: Teresa O. Bittenbender, Esq.

(215) 994-2213

123883.1.07